News
Awards & Honors
Spirit Scientific passes Japan PMDA audit for cell processing facilities, showcasing biofoundry™ strength
Spirit Scientific (7790) Becomes first company to receive PMDA certification for Platelet Lyophilization Processing Facilities On December 1, emerging biotech company Spirit Scientific (7790), listed on Taiwan's over-the-counter market, announced a major regulatory milestone. On November 20, the company received notification from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) under the Ministry of Health, Labour and Welfare (MHLW) confirming the successful completion of the overseas specified cell processing facility inspection. This achievement grants Spirit Scientific the Specified Cell Processed Products Manufacturing Certification from the Japanese MHLW, making it the first Taiwanese
Spirit Scientific BioTech Wins Ministry of Economic Affairs'”Startup Award,” Innovative Operating Strategy Recognized
Nov 19, 2025, The 24th "Startup Award" ceremony, hosted by the Ministry of Economic Affairs (MOEA), was grandly held yesterday at the NTUH International Convention Center. Spirit Scientific BioTech (7790), which focuses on precision regenerative medicine, was honored with the "Startup Award" in the Technology Industry category, demonstrating recognition for its technical innovation and outstanding operating performance.Spirit Scientific BioTech stated that it holds the core technology of Biological Material Lyophilization Technology (BMLT ®) and has developed an innovative service model: the Biofoundry™ Diamond-Grade Lyophilization Preparation Service. This model provides standardized and
Vice President acknowledge Golden Ship Award winners as Taiwan’s pride, showcase Taiwan’s strength to the world.
Vice President Meets with the Winners of the 7th Brand Golden Ship Award. Vice President Hsiao Bi-khim today (the 5th) met with the award-winning enterprises of the 7th Brand Golden Ship Award. She affirmed that the award-winning companies are the pride of Taiwan and emphasized that the government will support all sectors, serving as a strong backing for the industry. She expressed hope for a joint effort to showcase Taiwan's strength to the world. In her remarks, the Vice President stated that it was a great honor to receive the
Spirit Scientific won 2 special prizes in Golden Peak Award, and showcases hair growth innovations at AMWC Asia-TDAC 2025
Spirit Scientific (7790) showcased its high-concentration PLT services and new platelet-derived cellular signal factors lyophilization services at the 2025 Taiwan Dermatological Association Spring Academic Conference (AMWC Asia-TDAC 2025) held in Taipei. The company also announced its recent receipt of the prestigious "Golden Peak Award," earning "Top Ten Outstanding Products" and "Top Ten Outstanding Entrepreneurship Models." The conference, co-organized by the Taiwan Dermatological Association (TDA) and the Taiwan Society for Dermatologic and Cosmetic Surgery (TSDAS), is a major event in East Asia focusing on cutting-edge advancements in cosmetic medicine, dermatology, and
Spirit Scientific biotech won double prizes at Golden Peak Awards
Spirit Scientific biotech has been honored with two prestigious awards at the Golden Peak Awards ceremony held on the evening of April 25th. Competing against over 500 companies, Spirit Scientific's innovative high-concentration platelet lyophilized preparation service earned them the "Top Ten Outstanding Products" award. Furthermore, their Founder and Chairman, Lin Daolong, was recognized with the "Top Ten Outstanding Entrepreneurial Role Models" award. This marks a significant achievement, securing a double win for the company. The Golden Peak Awards, organized by the Chinese Management Association, is a benchmark award for innovative
思必瑞特PLT凍晶 傷口治療新選擇
思必瑞特與國際先進國家有相同的策略方法，利用自身專利PLT凍晶技術優勢，為病患治療提供了更加明確且便捷的新選擇 隨著細胞治療的開放，有更多的治療方法可以應用於傷口治療，思必瑞特與國際先進國家有相同的策略方法，利用自身專利PLT凍晶技術優勢，為病患治療提供了更加明確且便捷的新選擇。 三軍總醫院整形外科主任戴念梓表示，傷口治療是一個冗長的過程，從傷口發生到控制感染程度，以手術或藥物清創，再來是控制分泌物到癒合階段，當傷口面積過大，難以依靠病人自身的癒合能力時，這時便需要癒合手術介入，其中癒合手術又分為植皮手術、皮瓣手術等。 戴念梓說，尤其是燒燙傷治療，或糖尿病、靜脈曲張、動脈阻塞等病因會產生難以癒合的潰瘍傷口，針對這類慢性、困難修復型傷口，如何降低傷口感染機率，縮短癒合時間，就變得非常重要。 隨著近期細胞療法開放，也帶動更多新型療法，其中高濃度血小板血漿便是一例，打破傳統PRP需視病人的健康條件及當下抽取的濃度，來決定療程效果，新型的PLT凍晶粉，透過業者不斷改良與精進，導入了藥品等級概念，不但可準確控管純度及品質，且可將血小板定劑定量，經無菌化處理後，可於室溫保存3年，如此創新的PLT凍晶製品，勢必在未來有更多可能性，等待業界去發掘。 點此看工商時報報導
一種新的生長因子濃度標準化製備方法
濃縮的血小板凍晶粉可以解決現行PRP缺乏標準化、研究間缺乏一致性、以及缺乏詳述劑量等缺失。新的PRP凍晶粉為PRP研究以及患者治療開闢了新的可能性。 文獻：Platelet-Rich Plasma Powder: A New Preparation Method for the Standardization of Growth Factor Concentrations. Am J Sports Med. 2017 Mar; 45(4):954-960. 實驗設計：控制實驗研究法 實驗結果： 與全血相比，所有生長因子製備方法均顯示生長因子VEGF，bFGF，PDGF-AB和TGF-β1的濃度升高。在VEGF和bFGF濃度中發現較大的個體差異。血小板凍晶粉的生長因子（包含VEGF、PDGF-AB、TGF-β1）濃度顯著高於全血以及以Smart-Prep2和PC兩種製備方法所製成的PRP。 結論： 濃縮的血小板凍晶粉可以解決現行PRP缺乏標準化、研究間缺乏一致性、以及缺乏詳述劑量等缺失。新的PRP凍晶粉為PRP研究以及患者治療開闢了新的可能性。 臨床相關意義： 經由冷凍乾燥法 所製備的濃縮PRP凍晶粉，可幫助醫師以定劑定量的方式控制療程中的生長因子濃度。 血小板凍晶粉末是乾燥物質，因為無需離心且（製作完成後）方便取得，從而節省了臨床實驗所耗費的時間和人力 。 但是，在將這項基礎科學研究的結果轉移到臨床應用之前，必須釐清監管問題。
